Details for New Drug Application (NDA): 205220
✉ Email this page to a colleague
NDA 205220 describes VALGANCICLOVIR HYDROCHLORIDE, which is a drug marketed by Actavis Labs Fl Inc, Ajanta Pharma Ltd, Appco, Aurobindo Pharma, Granules, Hetero Labs Ltd V, Micro Labs, MSN, Aurobindo Pharma Ltd, Cipla, Dr Reddys, Pharmobedient, Somerset Theraps Llc, Sph Zhongxi Pharm, and Strides Pharma Intl, and is included in eighteen NDAs. It is available from twenty suppliers. Additional details are available on the VALGANCICLOVIR HYDROCHLORIDE profile page.
The generic ingredient in VALGANCICLOVIR HYDROCHLORIDE is valganciclovir hydrochloride. There are seventeen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the valganciclovir hydrochloride profile page.
The generic ingredient in VALGANCICLOVIR HYDROCHLORIDE is valganciclovir hydrochloride. There are seventeen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the valganciclovir hydrochloride profile page.
Summary for 205220
| Tradename: | VALGANCICLOVIR HYDROCHLORIDE |
| Applicant: | Actavis Labs Fl Inc |
| Ingredient: | valganciclovir hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 205220
| Mechanism of Action | DNA Polymerase Inhibitors |
Suppliers and Packaging for NDA: 205220
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VALGANCICLOVIR HYDROCHLORIDE | valganciclovir hydrochloride | FOR SOLUTION;ORAL | 205220 | ANDA | Actavis Pharma, Inc. | 0591-2579 | 0591-2579-20 | 100 mL in 1 BOTTLE, GLASS (0591-2579-20) |
| VALGANCICLOVIR HYDROCHLORIDE | valganciclovir hydrochloride | FOR SOLUTION;ORAL | 205220 | ANDA | AvKARE | 42291-972 | 42291-972-01 | 100 mL in 1 BOTTLE (42291-972-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SOLUTION;ORAL | Strength | 50MG/ML | ||||
| Approval Date: | Jul 18, 2016 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
